Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Page

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
NPJ Vaccines|June 30, 2023
Availability and use of Standards in vaccine developmentMichael Selorm Avumegah, Giada Mattiuzzo, Anna Särnefält, et al.
Plos One|August 20, 2011
Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaquesNeil Berry, Claire Ham, Edward T Mee, et al.
The Journal of General Virology|August 30, 2008
Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8)Neil Berry, Richard Stebbings, Debbie Ferguson, et al.
Plos One|August 28, 2014
Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissuesDeborah Ferguson, Giada Mattiuzzo, Claire Ham, et al.
BJU International|October 30, 2020
The experience of UK patients with bladder cancer during the COVID-19 pandemic: a survey-based snapshotSarah Spencer-Bowdage, Beth Russell, Jeannie Rigby, et al.
Vaccine|September 26, 2002
Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriersMaria-Christina Jung, Norbert Grüner, Reinhart Zachoval, et al.
BJUI Compass|August 10, 2022
The experience of UK patients with bladder cancer during the second wave of the COVID-19 pandemicBeth Russell, Sarah Spencer-Bowdage, Jeannie Rigby, et al.
Vaccine|December 29, 2010
Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulationMartin P Cranage, Carol A Fraser, Alethea Cope, et al.
Journal of Virology|August 16, 2019
Vaccination of Macaques with DNA Followed by Adenoviral Vectors Encoding Simian Immunodeficiency Virus (SIV) Gag Alone Delays Infection by Repeated Mucosal Challenge with SIVNeil Almond, Neil Berry, Richard Stebbings, et al.
Retrovirology|July 18, 2012
Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque modelMark Page, Richard Stebbings, Neil Berry, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
NPJ Vaccines|June 30, 2023
Availability and use of Standards in vaccine developmentMichael Selorm Avumegah, Giada Mattiuzzo, Anna Särnefält, et al.
Plos One|August 20, 2011
Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaquesNeil Berry, Claire Ham, Edward T Mee, et al.
The Journal of General Virology|August 30, 2008
Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8)Neil Berry, Richard Stebbings, Debbie Ferguson, et al.
Plos One|August 28, 2014
Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissuesDeborah Ferguson, Giada Mattiuzzo, Claire Ham, et al.
BJU International|October 30, 2020
The experience of UK patients with bladder cancer during the COVID-19 pandemic: a survey-based snapshotSarah Spencer-Bowdage, Beth Russell, Jeannie Rigby, et al.
Vaccine|September 26, 2002
Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriersMaria-Christina Jung, Norbert Grüner, Reinhart Zachoval, et al.
BJUI Compass|August 10, 2022
The experience of UK patients with bladder cancer during the second wave of the COVID-19 pandemicBeth Russell, Sarah Spencer-Bowdage, Jeannie Rigby, et al.
Vaccine|December 29, 2010
Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulationMartin P Cranage, Carol A Fraser, Alethea Cope, et al.
Journal of Virology|August 16, 2019
Vaccination of Macaques with DNA Followed by Adenoviral Vectors Encoding Simian Immunodeficiency Virus (SIV) Gag Alone Delays Infection by Repeated Mucosal Challenge with SIVNeil Almond, Neil Berry, Richard Stebbings, et al.
Retrovirology|July 18, 2012
Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque modelMark Page, Richard Stebbings, Neil Berry, et al.
Pageof 7